Pyrazolone Derivatives (Antipyrine,Aminopyrine,Phenylbutazone,Oxyphenbutazone)

Aggeler P. M. : Potentiation of Anticoagulant Effect of Warfarin by Phenylbutazone, New Engl. J. Med. 276: 496 (Mar. 2) 1967. (OCH).

Anon : Effects of Drugs on the PBI and Ta Uptake, Med. Letter 9: 82 (Oct. 20) 1967. (R).

Anton A. H. : A Drug-Induced Change in the Distribution and Renal Excretion of Sulfonamides, J. Pharmacol. Exptl. Therap. 129: 282, 1960. (OA).

Bluestone R. : Effects of Drugs on Urate Binding to Plasma Proteins, Brit. Med. J. 4: 590 (Dec. 6) 1969. (OH).

Burns J. J. : Application of Drug Metabolism to Drug Toxicity Studies, Ann. N.Y. Acad. Sci. 123: 273 (Mar.) 1965. (R).

Chen W. : Accelerated Aminopyrine Metabolism in Human Subjects Pretreated with Phenylbutazone, Life Sci. 2: 35, 1962.

Christensen L. K. Skovsted L. : Inhibition of Drug Metabolism by Chloramphenicol, Lancet 2: 1397 (Dec. 27) 1969. (OH).

Christensen L. K. : Sulphaphenazole-Induced Hypoglycaemic Attacks in Tolbutamide-Treated Diabetics, Lancet 2: 1298 (Dec. 21) 1963. (OCHT).

Conney A. H. Schneidman K. : Enhanced Androgen Hydroxylase Activity in Liver Microsomes of Rats and Dogs Treated with Phenylbutazone, J. Pharmacol. Exptl. Therap. 146: 225 (Nov.) 1964.

Conney A. H. : Drug-Induced Changes in Steroid Metabolism, Ann. N.Y. Acad. Sci. 123: 98 (Mar.) 1965. (R).

Conney A. H. : Effects of Pesticides on Drug and Steroid Metabolism, Clin. Pharmacol. Therap. 8: 2 (Jan.-Feb.) 1968. (OA).

Eddy J. D. Mackinnon J. : Anticoagulants-Butazolidin, Brit. Med. J. 3: 435 (Aug. 12) 1967. (CH).

Eisen M. J. : Combined Effects of Sodium Warfarin and Phenylbutazone, J. Am. Med. Assoc. 189: 64 (July 6) 1964. (CH).

Field J. B. : Potentiation of Acetohexamide Hypoglycemia by Phenylbutazone, New Engl. J. Med. 277: 889 (Oct. 26) 1967. (OH).

Fox S. L. : Potentiation of Anticoagulants Caused by Pyrazole Compounds, J. Am. Med. Assoc. 188: 320 (Apr. 20) 1964. (CH).

Goodman L. S. Gilman A. : The Pharmacological Basis of Therapeutics, 4th ed., Macmillan, N.Y. 1970 334a, 336b.

Hansen J. M. : Dicumarol-Induced Diphenylhydantoin Intoxication, Lancet 2: 265 (July 30) 1966. (OH).

Hoffbrand B. I. Kininmonth D. A. : Potentiation of Anticoagulants, Brit. Med. J. 2: 838 (June 24) 1967. (CH).

Kampfmeyer H. G. : Failure to Detect Increased Elimination Rate of Phenacetin in Man After Treatment with Phenobarbital, Klin. Wochschr. 47: 1237 (Oct.) 1969.

Kuntzman R. : Effect of Phenylbutazone on Cortisol Metabolism in Man, Pharmacologist 8: 195, 1966.

Levi A. J. : Phenylbutazone and Isoniazid Metabolism in Patients with Liver Disease in Relation to Previous Drug Therapy, Lancet 1: 1225 (June 15) 1968. (OH).

Lucas B. G. : “Dilantin” Overdosage (Correspondence), Med. J. Australia 2: 639 (Oct. 12) 1967.

Lunde P. K. M. : Plasma Protein Binding of Diphenylhydantoin in Man, Clin. Pharmacol. Therap. 11: 846 (Nov.–Dec.) 1970. (OTH).

Maickel R. P. : Pharmacologist 1: 182, 1965.

Mayer G. A. : A Rare Complication of Coumadin-Congener Anticoagulant Therapy (Correspondence), Can. Med. Assoc. J. 93: 1042 (Nov. 6) 1965.

McLaughlin G. E. : Hemarthrosis and Anticoagulants (Letters), Ann. Internal Med. 71: 867 (Oct.) 1969.

McLaughlin G. E. McCarthy O. J. : Hemarthrosis Complicating Anticoagulant Therapy, J. Am. Med. Assoc. 196: 1020 (June 13) 1966. (CH).

Mielens Z. E. : Interaction of Aspirin with Nonsteroidal Anti-Inflammatory Drugs in Rats (Letters), J. Pharm. Pharmacol. 20: 567 (July) 1968. (OA).

O'Reilly R. A. Levy G. : Pharmacokinetic Analysis of Potentiating Effect of Phenylbutazone on Anticoagulant Action of Warfarin in Man, J. Pharm. Sci. 59: 1258 (Sept.) 1970. (O).

Oyer J. H. : Suppression of Salicylate-Induced Uricosuria by Phenylbutazone, Am. J. Med. Sci. 251: 1 (Jan.) 1966. (OH).

Poland A. : Effect of Intensive Occupational Exposure to DDT on Phenylbutazone and Cortisol Metabolism in Human Subjects, Clin. Pharmacol. Therap. 11: 724 (Sept.-Oct.) 1970. (OH).

Solomon H. M. Schrogie J. J. : The Anticoagulant Response to Bishydroxycoumarin, I. The Role of Individual Variation, Clin. Pharmacol. Therap. 8: 65 (Jan.-Feb.) 1967. (OH).

Taylor P. J. : Hemorrhage While on Anticoagulant Therapy by Drug Interaction, Arizona Med. 24: 697 (Aug.) 1967. (CH).

Udall J. A. : Drug Interference with Warfarin Therapy, Am. J. Cardiol. 23: 143 (Jan.) 1969. (OH).

Vesell E. S. : Genetic Control of Phenobarbital Induced Shortening of Plasma Antipyrine Half-Lives in Man, J. Clin. Invest. 48: 2202 (Dec.) 1965. (OH).

Weiner M. : Drug Interactions: The Effect of Combined Administration on the Half-Life of Coumarin and Pyrazolone Drugs in Man, Fed. Proc. 24: 153, 1965.

Welch R. M. : An Experimental Model in Dogs for Studying Interactions of Drugs with Bishydroxycoumarin, Clin. Pharmacol. Therap. 10: 817 (Nov.–Dec.) 1969. (OA).

Whittaker J. A. : Genetic Control of Phenylbutazone Metabolism in Man, Brit. Med. J. 4: 323 (Nov. 7) 1970. Additional References Not Reviewed by This Author.

Kindermann A. : Vaskulares Allergid nack Butazolidin und Gefahren kombinieter Anwendung mit Athrombon (Phenylindandion), Dermatol. Wochschr. 143: 172, 1961.

Mathies H. : Experimental Studies in Humans on the Synergistic Action of Prednisolone and Phenylbutazone, (Ger.).

Sigg A. : Verstarkung der Antikoagulantienwirkung durch Butazolidin, Schweiz. Med. Wochschr. 86: 1194, 1956.

Riesterer L. Jacques R. : Interference by β-Adrenergic Blocking Agents with the Anti-Inflammatory Action of Various Drugs, Helv. Physiol. Acta 26: 287, 1968.

King T. M. Burgard J. K. : Drug Interactions, Am. J. Obstet. Gynecol. 98: 128 (May 1) 1967. (R).